HTG Molecular Diagnostics, Inc. HTGM NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

23/100

1/7 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

HTG Molecular Diagnostics, Inc. (HTGM) .

Criteria proven by this page:

VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($0.17, 65.3%).
Analyst consensus target $0.17 (-65.3% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 23/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

23/100

SG Score

View full scorecard →

✗

VALUE

10/100

Price-to-Earnings & upside

Proven by this page

✓

FUTURE

64/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

14/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — HTGM

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.07

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-24.28

Book Value / Share$0.00

Revenue / Share$7.16

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

Analyst Target$0.17 (-65.3%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2013	$-44.13	$2.24M	$-11.77M	-524.7%
2014	$-5.95	$3.33M	$-13.96M	-419.3%
2015	$-5.92	$4.04M	$-21.4M	-529.4%
2016	$-4.58	$5.13M	$-26.04M	-507.3%
2017	$-2.24	$14.76M	$-18.96M	-128.5%
2018	$-0.75	$21.5M	$-16.45M	-76.5%
2019	$-91.17	$19.2M	$-19.3M	-100.5%
2020	$-54.12	$8.55M	$-20.87M	-244.1%
2021	$-29.66	$8.91M	$-17.15M	-192.5%
2022	$-24.28	$6.37M	$-21.59M	-339.2%